Suven Life Sciences Initiating Coverage Report By Anand Rathi

Tagged: Anand Rathi, Suven Life Sciences

This topic has 0 replies, 1 voice, and was last updated 9 years, 10 months ago by Vidhi Khanna.

Viewing 1 post (of 1 total)

Author

Posts
January 30, 2015 at 9:36 pm #1682

Vidhi Khanna
Keymaster

We initiate coverage on Suven Life Sciences, with a Buy rating and a target price of Rs. 336. We are positive about the company considering its well-established niche business model with upward potential, sustainable revenue growth momentum, very high margins with no working-capital issues, a strong balance sheet and a 37% adjusted PAT CAGR over FY15-17e. In addition, successful monetisation of SUVN 502 (an innovative molecule) could offer further upside.

Suven Life Sciences_IC_21 January 2015
Author

Posts

Viewing 1 post (of 1 total)

You must be logged in to reply to this topic.